Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components

British Journal of Clinical Pharmacology

Volumn 48, Issue 4, 1999, Pages 543-552

  Eagling, V A ^a   Profit, L ^a   Back, D J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

CYP3A4; Grapefruit juice; P glycoprotein

Indexed keywords

AURANTIIN; BERGAMOTTIN; CYTOCHROME P450 ISOENZYME; FLAVANOID; GLYCOPROTEIN P; KETOCONAZOLE; NARINGENIN; QUERCETIN; SAQUINAVIR; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CELL STRAIN CACO 2; CITRUS FRUIT; CONTROLLED STUDY; DRUG TRANSPORT; ENZYME INHIBITION; ENZYME METABOLISM; FOOD DRUG INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MONOLAYER CULTURE; NORMAL HUMAN; PRIORITY JOURNAL;

BEVERAGES; CACO-2 CELLS; CITRUS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HIV PROTEASE INHIBITORS; HUMANS; KETOCONAZOLE; LIVER; MIXED FUNCTION OXYGENASES; P-GLYCOPROTEIN; PLANT EXTRACTS; SAQUINAVIR; TIME FACTORS; VERAPAMIL;

EID: 0032865554     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00052.x     Document Type: Article

References (51)

1. 1 Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-269.
2. 2 Bailey DG, Arnold JR, Bend LT, et al. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release formulation. Br J Clin Pharmacol 1995; 40: 135-140.
3. 3 Ducharme MP, Provenzano R, Dehoorne Smith M, Edwards DJ. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993; 36: 457-459.
4. 4 Ducharme MP, Warbasse LH, Edwards DJ. Disposition of oral and intravenous cyclosporin after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485-491.
5. 5 Kupferschmidt HH, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 50: 20-28.
6. 6 Benton RE, Hoing PK, Zamani LR, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolonged repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59: 383-388.
7. 7 Paine MF, Shen DD, Kunze KL, et al. First pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60: 14-24.
8. 8 Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991, 338: 1488-1490.
9. 9 Wu CY, Benet LZ, Herbert SK, et al. Differentiation of absorption and first pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58: 492-497.
10. 10 Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80: 1029-1036.
11. 11 Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of Rifampicin-inducible P4503A4 in human small bowel enterocytes. J Clin Invest 1992; 90: 1871-1878.
12. 12 Lundahl JUE, Regardth CG, Edgar B, Johnsson G. The interaction effect of grapefruit juice is maximal after the first glass. Eur J Clin Pharmacol 1998; 54: 75-81.
13. 13 Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2545-2553.
14. 14 Schmeidlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral bioavailability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228-1233.
15. 15 Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248-260.
16. 16 Fricker G, Huwyler DJ, Gutmann H, Beglinger C. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A. in vitro-in vivo correlation. Br J Pharmacol 1996; 118: 1841-1847.
17. 17 Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-269.
18. 18 Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrate specificities and tissue distribution of Cytochrome P450, 3A and P-glycoprotein: implications for drug delivery in cancer chemotherapy. Molec Carcin 1995; 13: 129-134.
19. 19 Stewart BH, Chan OH, Lu RH, et al. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relation to absorption in humans. Pharm Res 1995; 12: 693-699.
20. 20 Pinto M, Robine-Leon S, Appay M D, et al. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco 2 in culture. Bio Cell 1983; 47: 323-330.
21. 21 Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989; 96: 736-749.
22. 22 Hunter J, Jepson MA, Tsuruo T, et al. Functional expression of P-glycoprotein in apical membrane of human intestinal Caco 2 cells. J Biol Chem 1993; 268: 14991-14997.
23. 23 Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
24. 24 Washigton CB, Duran GE, Silkic BI, et al. Saquinavir is a high affinity substrate for the multidrug transporter, P glycoprotein. Clin Pharmacol Ther 1997; 63: OII-A-3.
25. 25 Kim RB, Fromm MF, Wandel C, et al. The drug transporter P glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1988; 101: 289-294.
26. 26 Lee CGL, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37: 3594-3601.
27. 27 Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small intestinal cytochrome P450. Drug Metab Dispos 1997; 25: 256-267.
28. 28 Kupferschmidt HHT, Fattinger KE, Ha HR, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998; 45: 355-359.
29. 29 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein determination with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
30. 30 Edwards DJ, Bellevue FH, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome-P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996; 24: 1287-1290.
31. 31 Bellevue FH, Woster PM, Edwards DJ, et al. Synthesis and biological evaluation of 6′,7′-dihydroxybergamottin (6,7-DHB), a naturally occurring inhibitor of cytochrome P450 3A4. Bioorg Med Chem Lett 1997; 7: 2593-2598.
32. 32 Bailey DG, Monoz C, Kreeft JH, et al. Grapefruit juice -felodipine interaction: amount and effect of active ingredients in juice fraction in man. Clin Pharmacol Ther 1998; 63: [(Abstract) PI-99].
33. 33 He K, Iyer KR, Hayes RN, et al. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998; 11: 252-259.
34. 34 Guengerich FP, Kim D-H. In vitro inhibition of dihydropyridine oxidation and aflatoxin B activation in human liver microsomes by naringenin and other flavinoids. Carcinogenesis 1990; 11: 2275-2279.
35. 35 Miniscalco A, Lundahl J, Regardh CG, et al. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Therapeut 1992; 261: 1195-1199.
36. 36 Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharmaceut Res 1998; 15: 423-428.
37. 37 Noble S, Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996; 52: 93-112.
38. 38 Bailey DG, Kreeft JH, Munoz C, et al. Grapefruit juice-felodipine interaction: effect of naringin and 6′,7′-dihydroxybergamottin in humans. Clin Pharmacol Ther 1998; 64: 248-256.
39. 39 Edwards DJ, Fitzsimmons ME, Schwatz EG, et al. 6′,7′-dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4 and p-glycoprotein. Clin Pharmacol Ther 1999; 65: 237-244.
40. 40 Walgren RA, Walle UK, Walle T. Transepithelial absorption of quercetin and quercetin glucosides across the Caco-2 human intestinal cell line. Clin Pharmacol Ther 1998; 63: [(Abstract) PIII-20].
41. 41 Scambia G, Ranelletti FO, Panici PB, et al. Quercetin potentiates the effect of adriamycin in a multidrug resistant MCF-7 human breast cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 1994; 34: 459-464.
42. 42 Takanaga H, Ohnishi A, Matsuo H, Sawada Y. Inhibition of vinblastine efflux mediated by p-glycoprotein by grapefruit juice components in Caco 2 cells. Biol Pharm Bull 1998; 21: 1062-1066.
43. 43 Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695-698.
44. 44 Pang S, Koyangi Y, Miles S, et al. High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature 1990; 34: 85-89.
45. 45 Chaudhary PM, Roninson IB. Expression and activity of P glycoprotein, a multidrug efflux pump, in human haematopoietic stem cells. Cell 1991; 66: 85-94.
46. 46 Gupta S, Kim CH, Tsuruo T, et al. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein) a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J Clin Immunol 1993; 12: 451-458.
47. 47 Chaudhary PM, Mechetner EB, Roninson IB, et al. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735-2739.
48. 48 Pilarski LM, Paine D, McElhaney JE, et al. Multidrug transporter P glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: modulation with differentiation stage and during ageing. Am J Hematol 1995; 49: 323-325.
49. 49 Wong JK, Hezareh HF, Gunthard DV, et al. Recovery of replication competent HIV despite prolonged suppression of plasma viraemia. Science 1997; 278: 1291-1295.
50. 50 Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 replication in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-1300.
51. 51 Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94: 13193-13197.